Patent ID: 11896646
Assignee: NAMMI THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A

Claim 8:
9. The nanocarrier of claim 4, whereby the nanocarrier is further co-formulated with an immune modulating agent, wherein the immune modulating agent is selected from the group consisting of other TLR agonists and/or prodrugs, immunogenic-cell death inducing chemotherapeutics, IDO (indoleamine 2,3-dioxygenase) antagonists, STING (stimulator of interferon genes) agonists, CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) inhibitors, PD-1/PD-L1 (programmed cell death 1/programmed cell death ligan 1) inhibitors and/or prodrugs thereof.